Liquidia (NASDAQ:LQDA) Stock Rating Reaffirmed by Wedbush

view original post

Liquidia (NASDAQ:LQDA)‘s stock had its “hold” rating reiterated by equities research analysts at Wedbush in a report issued on Friday, Analyst Ratings Network reports. They presently have a $6.00 target price on the stock. Wedbush’s price target suggests a potential downside of 4.15% from the company’s current price. Wedbush also issued estimates for Liquidia’s FY2026 earnings at ($0.10) EPS.

A number of other equities research analysts have also issued reports on the stock. Needham & Company LLC raised their price target on shares of Liquidia from $5.00 to $8.00 and gave the stock a “buy” rating in a report on Monday, November 8th. Zacks Investment Research lowered shares of Liquidia from a “hold” rating to a “sell” rating in a report on Tuesday, November 9th.

Shares of NASDAQ:LQDA opened at $6.26 on Friday. The stock has a market cap of $325.39 million, a PE ratio of -7.28 and a beta of 0.26. The company’s fifty day moving average is $4.49 and its 200 day moving average is $3.36. Liquidia has a 52 week low of $2.25 and a 52 week high of $6.67.

Liquidia (NASDAQ:LQDA) last issued its earnings results on Wednesday, November 3rd. The company reported ($0.14) EPS for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.02). The business had revenue of $3.18 million during the quarter, compared to analysts’ expectations of $2.48 million. Liquidia had a negative return on equity of 71.68% and a negative net margin of 376.75%. On average, equities research analysts predict that Liquidia will post -0.59 EPS for the current fiscal year.

In related news, Director Arthur S. Kirsch bought 30,000 shares of the business’s stock in a transaction dated Wednesday, November 10th. The shares were purchased at an average price of $4.24 per share, with a total value of $127,200.00. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. Also, General Counsel Russell Schundler bought 117,908 shares of the business’s stock in a transaction dated Wednesday, November 10th. The shares were bought at an average cost of $4.21 per share, for a total transaction of $496,392.68. The disclosure for this purchase can be found here. 29.50% of the stock is owned by company insiders.

Institutional investors and hedge funds have recently made changes to their positions in the company. Boothbay Fund Management LLC boosted its stake in shares of Liquidia by 11.1% during the 2nd quarter. Boothbay Fund Management LLC now owns 109,638 shares of the company’s stock valued at $314,000 after purchasing an additional 10,922 shares in the last quarter. Tibra Equities Europe Ltd bought a new stake in Liquidia during the second quarter worth about $339,000. Deutsche Bank AG boosted its stake in Liquidia by 654.6% during the second quarter. Deutsche Bank AG now owns 138,853 shares of the company’s stock worth $397,000 after acquiring an additional 120,451 shares in the last quarter. Sigma Planning Corp boosted its stake in Liquidia by 21.5% during the second quarter. Sigma Planning Corp now owns 34,490 shares of the company’s stock worth $99,000 after acquiring an additional 6,100 shares in the last quarter. Finally, XTX Topco Ltd bought a new stake in Liquidia during the second quarter worth about $62,000. 20.48% of the stock is currently owned by hedge funds and other institutional investors.

Liquidia Company Profile

Liquidia Corp. operates as a holding company which through its subsidiary engages in developing and commercializing biopharmaceutical products. It engages in novel products development used in PRINT technology to transform the lives of patients. PRINT is a particle engineering platform that enables precise production of uniform drug particles designed to improve the safety, efficacy and performance of a wide range of therapies.

See Also: Fiduciary

Want More Great Investing Ideas?

Related Posts